Read by QxMD icon Read

Breast Cancer Research and Treatment

Kelly Kyker-Snowman, Bracha Erlanger Avigdor, Mansoor Nasim, Ashley Cimino-Mathews, Sarah J Wheelan, Pedram Argani, Ben Ho Park
BACKGROUND/PURPOSE: Tumor heterogeneity is a now well-recognized phenomenon that can affect the classification, prognosis and treatment of human cancers. Heterogeneity is often described in primary breast cancers based upon histologic subtypes, hormone- and HER2-receptor status, and immunolabeling for various markers, which can be seen within a single tumor as mixed cellular populations, or as separate discrete foci. EXPERIMENTAL DESIGN/METHODS: Here, we present a case report of a patient's primary breast cancer that had two separate but adjacent histologic components, one that was estrogen receptor (ER) positive, and the other ER negative...
March 15, 2018: Breast Cancer Research and Treatment
Salehoddin Bouya, Maryam Koochakzai, Hosein Rafiemanesh, Abbas Balouchi, Safiyeh Taheri, Mahin Badakhsh, Mahnaz Didehvar
PURPOSE: Quality of life is the most important psychological factor affecting breast cancer patients. This study aimed to examine the health related quality of life of breast cancer patients in Iran. METHODS: International (PubMed, Web of science, Scopus and Google scholar) and national (SID, Magiran) databases were searched for related studies to September 2017. The quality of the articles was evaluated using the Hoy tool. RESULTS: Out of 232 initial studies, 18 studies performed on 2263 people were included in the final stage of the study...
March 14, 2018: Breast Cancer Research and Treatment
Steven A Narod
No abstract text is available yet for this article.
March 14, 2018: Breast Cancer Research and Treatment
Lauren E Wilson, Craig Evan Pollack, Melissa A Greiner, Michaela A Dinan
PURPOSE: We sought to determine whether physician-level characteristics were associated with 21-gene recurrence score (RS) genomic testing to evaluate recurrence risk and benefit of adjuvant chemotherapy in patients with estrogen receptor-positive, node-negative breast cancer. METHODS: Retrospective cohort study of a nationally representative sample of Medicare beneficiaries using Surveillance, Epidemiology, and End Results program-Medicare data linked with the American Medical Association physician master file...
March 13, 2018: Breast Cancer Research and Treatment
Philippe Autier
No abstract text is available yet for this article.
March 13, 2018: Breast Cancer Research and Treatment
Wendy Yen Yun Chou, Deborah J Veis, Rebecca Aft
PURPOSE: Radial scar's stellate appearance may mimic carcinoma mammographically and histologically. Management of radial scar (RS) found on breast core needle biopsies (CNB) ranges from excision to clinical observation due to the variation in reported upgrades to malignancy at surgical excision. We examined the upgrade rate in patients with RS detected on CNB at our institution and reviewed the current literature. METHODS: A retrospective study was conducted of all cases with RS diagnosed on CNB between December 2006 and March 2017 at our institution...
March 12, 2018: Breast Cancer Research and Treatment
Tia H Turner, Mohammad A Alzubi, Sahib S Sohal, Amy L Olex, Mikhail G Dozmorov, J Chuck Harrell
PURPOSE: Basal-like breast cancers are aggressive and often metastasize to vital organs. Treatment is largely limited to chemotherapy. This study aims to characterize the efficacy of cancer therapeutics in vitro and in vivo within the primary tumor and metastatic setting, using patient-derived xenograft (PDX) models. METHODS: We employed two basal-like, triple-negative PDX models, WHIM2 and WHIM30. PDX cells, obtained from mammary tumors grown in mice, were treated with twelve cancer therapeutics to evaluate their cytotoxicity in vitro...
March 12, 2018: Breast Cancer Research and Treatment
P Roy, A Leizorovicz, R Villet, C Mercier, J Y Bobin
PURPOSE: Sentinel-lymph-node (SLN) resection seems to minimize systematic axillary-lymph-node dissection (sALND) side effects in operated breast cancer patients. We explored whether SLN resection achieves similar therapeutic outcomes as sALND but with fewer side effects. METHODS: A randomized, controlled, open-label trial with parallel-group design compared sALND restricted to cases with positive SLN biopsy (test arm, n = 774) versus SLN biopsy followed by sALND (control arm, n = 770)...
March 10, 2018: Breast Cancer Research and Treatment
Yanchun Li, Mateusz Opyrchal, Song Yao, Xuan Peng, Li Yan, Hossam Jabbour, Thaer Khoury
PURPOSE: The purpose of the study is to investigate the prognostic significance of programmed death ligand-1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2+ breast cancer (BC). METHODS: HER2+ BC cases (n  = 191) were collected between 1996 and 2013. Tissue microarray (TMA) slides were stained with two clones of PD-L1 antibodies (28-8 and 22C3) and the percentage of positive membranous staining was scored. TILs of the full sections were also scored using percentage scale...
March 9, 2018: Breast Cancer Research and Treatment
Ting Bao, Wanqing Iris Zhi, Emily A Vertosick, Qing Susan Li, Janice DeRito, Andrew Vickers, Barrie R Cassileth, Jun J Mao, Kimberly J Van Zee
PURPOSE: Approximately 20% of breast cancer survivors develop breast cancer-related lymphedema (BCRL), and current therapies are limited. We compared acupuncture (AC) to usual care wait-list control (WL) for treatment of persistent BCRL. METHODS: Women with moderate BCRL lasting greater than six months were randomized to AC or WL. AC included twice weekly manual acupuncture over six weeks. We evaluated the difference in circumference and bioimpedance between affected and unaffected arms...
March 8, 2018: Breast Cancer Research and Treatment
P S Blanchette, D N Desautels, G R Pond, J M S Bartlett, S Nofech-Mozes, M J Yaffe, K I Pritchard
PURPOSE: We have limited capability to predict survival among patients treated for metastatic HER2-positive breast cancer. Further research is warranted to identify significant prognostic and predictive factors. METHODS: We identified all HER2-positive metastatic breast cancer patients receiving trastuzumab at the Sunnybrook Odette Cancer Centre (SOCC) from 1999 to 2013 through the Cancer Care Ontario (CCO) Registry (n = 256) and selected patients with available pathology reports (n = 154)...
March 8, 2018: Breast Cancer Research and Treatment
Soo Jin Park, Moo Hyun Lee, Sun-Young Kong, Mi Kyung Song, Jungnam Joo, Youngmee Kwon, Eun-Gyeong Lee, Jai Hong Han, Sung Hoon Sim, So-Youn Jung, Seeyoun Lee, Keun Seok Lee, In Hae Park, Eun Sook Lee
PURPOSE: We assessed the use of chemotherapy in breast cancer patients to investigate the factors that changed trends in chemotherapy following the adoption of the 21-gene expression assay in tumor genomic profiling. METHODS: Our study used 2033 patients from the National Cancer Center in Korea diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (tumor size of 0.5 cm or larger and 0-3 node metastases) from 2010 to 2015...
March 8, 2018: Breast Cancer Research and Treatment
Héctor A Velásquez García, Boris G Sobolev, Carolyn C Gotay, Christine M Wilson, Caroline A Lohrisch, Agnes S Lai, Kristan J Aronson, John J Spinelli
PURPOSE: The association between high mammographic density (MD) and elevated breast cancer risk is well established. However, the role of absolute non-dense area remains unclear. We estimated the effect of the mammographic non-dense area and other density parameters on the risk of breast cancer. METHODS: This study utilizes data from a population-based case-control study conducted in Greater Vancouver, British Columbia, with 477 female postmenopausal breast cancer cases and 588 female postmenopausal controls...
March 7, 2018: Breast Cancer Research and Treatment
T Onega, W Zhu, J E Weiss, M Goodrich, A N A Tosteson, W DeMartini, B A Virnig, L M Henderson, D S M Buist, K J Wernli, K Kerlikowske, R A Hubbard
PURPOSE: The survival benefit from detecting additional breast cancers by preoperative magnetic resonance imaging (MRI) continues to be controversial. METHODS: We followed a cohort of 4454 women diagnosed with non-metastatic breast cancer (stage I-III) from 2/2005-6/2010 in five registries of the breast cancer surveillance consortium (BCSC). BCSC clinical and registry data were linked to Medicare claims and enrollment data. We estimated the cumulative probability of breast cancer-specific and all-cause mortality...
March 7, 2018: Breast Cancer Research and Treatment
Brian D Adams, Hannah Arem, Monica J Hubal, Brenda Cartmel, Fangyong Li, Maura Harrigan, Tara Sanft, Christopher J Cheng, Lajos Pusztai, Melinda L Irwin
PURPOSE: Obesity and weight gain are associated with comorbidities including a higher risk of tumor recurrence and cancer-related deaths among breast cancer (BC) survivors; however, the underlying mechanisms linking obesity and cancer are poorly understood. Given the lack of clinically validated BC biomarkers, obesity and weight-loss studies utilize serum biomarkers as the intermediary outcomes of tumor recurrence. Studies have indicated microRNAs (miRNA)s are reliable biomarkers for cancer...
March 6, 2018: Breast Cancer Research and Treatment
Marzana Chowdhury, David Euhus, Maureen O'Donnell, Tracy Onega, Pankaj K Choudhary, Swati Biswas
PURPOSE: Increased mammographic breast density is a significant risk factor for breast cancer. It is not clear if it is also a risk factor for the development of contralateral breast cancer. METHODS: The data were obtained from Breast Cancer Surveillance Consortium and included women diagnosed with invasive breast cancer or ductal carcinoma in situ between ages 18 and 88 and years 1995 and 2009. Each case of contralateral breast cancer was matched with three controls based on year of first breast cancer diagnosis, race, and length of follow-up...
March 6, 2018: Breast Cancer Research and Treatment
Megan S Rice, Rulla M Tamimi, Kimberly A Bertrand, Christopher G Scott, Matthew R Jensen, Aaron D Norman, Daniel W Visscher, Yunn-Yi Chen, Kathleen R Brandt, Fergus J Couch, John A Shepherd, Bo Fan, Fang-Fang Wu, Lin Ma, Laura C Collins, Steven R Cummings, Karla Kerlikowske, Celine M Vachon
BACKGROUND: Though mammographic density (MD) has been proposed as an intermediate marker of breast cancer risk, few studies have examined whether the associations between breast cancer risk factors and risk are mediated by MD, particularly by tumor characteristics. METHODS: Our study population included 3392 cases (1105 premenopausal) and 8882 (3192 premenopausal) controls from four case-control studies. For established risk factors, we estimated the percent of the total risk factor association with breast cancer that was mediated by percent MD (secondarily, by dense area and non-dense area) for invasive breast cancer as well as for subtypes defined by the estrogen receptor (ER+/ER-), progesterone receptor (PR+/PR-), and HER2 (HER2+/HER2-)...
March 3, 2018: Breast Cancer Research and Treatment
Sofie A M Gernaat, Jolanda M A Boer, Desiree H J van den Bongard, Angela H E M Maas, Carmen C van der Pol, Rhodé M Bijlsma, Diederick E Grobbee, Helena M Verkooijen, Petra H Peeters
OBJECTIVES: This study evaluates the risk of cardiovascular disease (CVD) following breast cancer, accounting for baseline CVD risk. METHODS: Within the EPIC-NL (Dutch part of the European Prospective Investigation into Nutrition and Cancer) cohort, 1103 women were diagnosed with breast cancer. For every breast cancer patient, 3-4 women without breast cancer (n = 4328) were selected matched for age, year, and time since cohort enrollment. Based on CVD risk factors at cohort enrollment, 10-year risk of CVD was calculated and categorized: low (< 10%), intermediate (10-20%), high (> 20%)...
February 28, 2018: Breast Cancer Research and Treatment
Carolyn J Kushner, Wei-Ting Hwang, Shiyu Wang, Lawrence J Solin, Neha Vapiwala
PURPOSE: Women with ductal carcinoma in situ (DCIS) or early-stage breast cancer have an excellent prognosis, but their risk of developing second malignant neoplasms (SMNs) is not well established. We analyzed SMNs in a large cohort with long follow-up after breast conservation therapy. METHODS: The study population comprised 755 women with DCIS (n = 135) or stage I-II breast carcinoma (n = 620). Subjects were aged 25-89 (median 55) years when they underwent breast-conserving surgery followed by radiotherapy to the entire breast (60-68Gray) between 1992 and 2001...
February 27, 2018: Breast Cancer Research and Treatment
Rui Chen, Yin Ye, Chengcheng Yang, Yang Peng, Beige Zong, Fanli Qu, Zhenrong Tang, Yihua Wang, Xinliang Su, Hongyuan Li, Guanglun Yang, Shengchun Liu
PURPOSE: To assess the predictive role of pretreatment ki67 and Ki67 changes in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) in various molecular subtypes. METHODS: 1010 BC patients who had undergone anthracycline and taxane-based NAC from January 2012 to July 2017 were retrospectively analyzed. Clinical and pathological parameters of the patients were retrieved and the predictive factors for NAC response were evaluated. RESULTS: 705 patients showed clinical response (cRes), and 131 patients acquired pathologic complete response (pCR)...
February 26, 2018: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"